Negative in Ames, in vitro chromosome aberration (CHL cells) and rat bone marrow micronucleus assays
“Lazertinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in either the in vitro chromosome aberration assay in Chinese hamster lung cells or the in vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity
Not conducted (advanced cancer indication)
“The Applicant did not conduct carcinogenicity studies to support the currently proposed indication (NSCLC), and these studies are not needed to support a marketing application for a drug intended to treat patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat and rabbit EFD; rabbit vertebral and skull malformations at 45 mg/kg
“There was an increase in the incidence of skeletal malformations in the vertebra and skull (fused maxillary process/zygomatic arch), and unossified hyoid skull (skeletal variation) at 45 mg/kg compared to controls.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
“The unbound Cmax of lazertinib at the recommended human dose of 240 mg calculated by the FDA nonclinical team is ~6 nM, thus the 5.3 μM IC50 for hERG channel inhibition corresponds to an ~883-fold multiple.”
✓ VerifiedFDA multi-discipline review, p. 54Source ↗
Genotox: Ames
Negative
“Lazertinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in either the in vitro chromosome aberration assay in Chinese hamster lung cells or the in vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
“Lazertinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in either the in vitro chromosome aberration assay in Chinese hamster lung cells or the in vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Genotox: in vivo
Rat bone marrow micronucleus: negative
“Lazertinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in either the in vitro chromosome aberration assay in Chinese hamster lung cells or the in vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity model
Not conducted (not needed for advanced cancer)
“The Applicant did not conduct carcinogenicity studies to support the currently proposed indication (NSCLC), and these studies are not needed to support a marketing application for a drug intended to treat patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity timing
Not required for advanced cancer indication (NSCLC)
“The Applicant did not conduct carcinogenicity studies to support the currently proposed indication (NSCLC), and these studies are not needed to support a marketing application for a drug intended to treat patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
hERG / QT
hERG IC50 5.3 µM, ~883-fold the unbound Cmax (~6 nM) at 240 mg
“The unbound Cmax of lazertinib at the recommended human dose of 240 mg calculated by the FDA nonclinical team is ~6 nM, thus the 5.3 μM IC50 for hERG channel inhibition corresponds to an ~883-fold multiple.”
✓ VerifiedFDA multi-discipline review, p. 54Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative